<DOC>
	<DOCNO>NCT00021372</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine paclitaxel estramustine treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Paclitaxel Estramustine Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , time treatment failure , overall survival patient relapse refractory non-Hodgkin 's lymphoma treat paclitaxel estramustine . II . Determine toxicity regimen patient population . OUTLINE : Patients receive oral estramustine 2-3 time daily day 1-3 paclitaxel IV 1 hour day 2 week 1-6 . Treatment repeat every 8 week least 1 course absence disease progression unacceptable toxicity . Patients achieve complete partial response continue therapy least 3 course 1 course achieve maximum response . Patients follow every 3 month . PROJECTED ACCRUAL : A total 18-35 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapsed refractory intermediate , highgrade , transform nonHodgkin 's lymphoma Received 13 prior treatment regimen ( cytoreductive chemotherapy follow highdose therapy stem cell support consider 1 regimen ) Measurable disease A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Granulocyte count great 1,500/mm3* Platelet count great 75,000/mm3* * Unless due lymphomatous marrow involvement Hepatic : Bilirubin le 1.5 mg/dL* SGOT/SGPT le 2 time normal* * Unless due lymphomatous involvement Renal : Creatinine le 2.0 mg/dL* OR Creatinine clearance great 50 mL/min* * Unless due lymphomatous involvement Cardiovascular : No active uncontrolled angina pectoris No New York Heart Association class IIIV heart disease No myocardial infarction within past 6 month No history recurrent deep venous thrombosis associate catheter placement Other : No prior malignancy within past 5 year except curatively treated cervical cancer basal cell squamous cell skin cancer No serious concurrent medical illness would preclude study No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover No prior paclitaxel , docetaxel , estramustine Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>